Category Archives: Tekturna

Featured Stories

Majority of Metal-on-Metal Hip Implant Failures Occur within Two Years, Study Finds

A newly published metal-on-metal hip replacement study is reporting that the majority of failures occur early, within two years of surgery. The study, published in the journal Orthopedics, is just the latest to indicate that close follow-up of metal-on-metal hip implant patients is warranted.

Read More

Three Injured, Long Island Railroad Train Hits Car on Tracks

Three Injured When Long Island Railroad Train Hits Car on Tracks

Three people, including a train engineer, were injured on Wednesday when a Long Island Rail Road train hit a livery cab on the tracks west of Wyandanch station, LIRR officials said. LIRR spokesman Salvatore Arena said the driver of the Lincoln Town Car was taken to Good Samaritan Hospital Medical Center ...

Read More

Geodon the antipsychotic drug can Cause Deadly Skin Reaction

Geodon can Cause Deadly Skin Reaction, FDA Warns

The FDA has required a new warning label for the antipsychotic drug Geodon (ziprasidone) to include the risk of a potentially fatal skin reaction.

Read More

FDA Panel Takes up Metal-on-Metal Hip Implant Safety Today

The Food and Drug Administration (FDA) is convening a meeting starting today to help decide the future of metal-on-metal hip implants following high-profile recalls and mounting questions about their overall safety.

Read More

Estate of Kentucky Man Alleges Wrongful Death Due to Actos Bladder Cancer

National law firm, Parker Waichman LLP, just filed a lawsuit on behalf of the estate of a Kentucky man who developed bladder cancer and subsequently died, allegedly due to the use of diabetes drug, Actos. The lawsuit names Takeda Pharmaceuticals America, Inc., Takeda Pharmaceuticals USA, Inc., Takeda Pharmaceuticals North America, ...

Read More

Medtronic Plans Layoffs, as Infuse Bone Graft Controversy Continues to Weigh on Spinal Business

Medtronic’s spinal division continues to take a huge hit thanks to the controversy surrounding its Infuse Bone Graft product. According to a report from MassDevice.com, the company’s latest earnings report stated that the division saw Infuse sales decline 26% in the first quarter of 2012, and now Medtronic is talking ...

Read More

Actos Bladder Cancer Lawsuits Continue, New Complaint Filed by Tennessee Resident

Actos bladder cancer lawsuits continue, with a new complaint filed by a resident of Tennessee. The national law firm, Parker Waichman LLP, represents the Tennessee man who alleges that Actos caused his bladder cancer.

Read More

British Recall of Smith & Nephew Renasys Wound Care System

British Recall of Smith & Nephew Renasys Wound Care System for Infection Risk

The MHRA announced the recall of Smith & Nephew Renasys wound care devices - risk of maceration, infection, loss of negative pressure, or unrecognized bleeding in wounds.

Read More

Former Executives Accuse Health Technology Firm of Fraud

Former Executives Accuse Health Technology Firm of Fraud

Former NantHealth executives claim that the company made fraudulent claims about the reliability of its system, which links patient information gathered by the devices.

Read More

Canadian Warning Issued for Actos Bladder Cancer Side Effect Risk

Health Canada has become the most recent national drug regulator to issue a warning about Actos and bladder cancer. Last month, the agency warned that interim results from a 10-year-study indicated that patients taking Actos for more than a year faced an increased risk of bladder cancer. Health Canada also ...

Read More

Drug Maker, Novartis, Accused Again of Kickback Schemes

We have long noted that the financial relationships between the drug and the health care industries have led to enormous controversy. Critics maintain that such relationships create conflicts of interest and could unduly influence everything from research findings to prescribing … Continue reading

Posted in Consumer Fraud, Legal News, Pharmaceuticals, Tekturna |

U.S. Prosecutors Investigating Novartis Marketing of Blood Pressure Drug Tekturna

U.S. prosecutors are investigating European drug manufacturer Novartis for its marketing of products including hypertension drug Tekturna. In a recent regulatory filing, Swiss-based Novartis revealed that, last year, a U.S. unit of the company received a subpoena from federal prosecutors … Continue reading

Posted in Health Concerns, Legal News, Pharmaceuticals, Tekturna |

Analysis of adverse event reports questions benefit of blood pressure drug Tekturna

A recent analysis of adverse health events linked to certain prescription drugs identified 100 incidents linked to the blood pressure medication Tekturna in just the first part of this year. The Institute for Safe Medication Practices (ISMP) combed a database … Continue reading

Posted in Pharmaceuticals, Tekturna | Tagged |

Tekturna Linked to Significant Number of Adverse Events

Independent watchdog group, the Institute for Safe Medical Practices (ISMP) reports a 90 percent increase in significant adverse drug event reports received by the U.S. Food & Drug Administration (FDA) over the past four years. Among these, are events associated … Continue reading

Posted in Pharmaceuticals, Tekturna |

Tekturna Label Changes, Valturna Market Withdrawal Announced by Novartis

Novartis announced yesterday that the label for the blood pressure drug Tekturna (aliskiren) will be updated with new warnings regarding its use in people with diabetes and kidney problems. Novartis also announced it will no longer market Valturna, a single-pill … Continue reading

Posted in Pharmaceuticals, Tekturna | Tagged |

Tekturna (Aliskiren) Associated with Serious Side Effects, Including Stroke, Severe Kidney Damage

Tekturna (aliskiren) and other medications containing aliskiren have been associated with serious side effects, including non-fatal stroke and severe kidney damage, in some patients. Tekturna and other aliskiren products were recently the subject of safety warnings in Europe (where it … Continue reading

Posted in Pharmaceuticals, Tekturna | Tagged |

MHRA Issues New Contraindications, Recommendations for Rasilez (Aliskiren) with ACE Inhibitors, ARBs

Health regulators in the U.K. have announced new contraindications and warnings regarding Rasilez (aliskiren), a blood pressure drug which is sold as Tekturna in the U.S. According a Drug Safety Update issued by the Medicine and Healthcare Products Regulatory Agency, … Continue reading

Posted in Pharmaceuticals, Tekturna |

Novartis Updates Rasilez Label in Europe with New Warnings for Diabetes, Kidney Patients

The blood pressure drug Rasilez – sold in the U.S. under the brand name Tekturna – will soon bear new safety warnings on its European label, after a clinical trial was halted because subject patients experienced a high rate of … Continue reading

Posted in Pharmaceuticals, Tekturna |

Canada Issues Warning, Updates Labeling For Rasilez

Canada just issued a warning for Rasilez, a high blood pressure drug known as Tekturna in the United States. Novartis Pharmaceuticals, Canada Inc makes Rasilez. Health Canada and Novartis issued the warning for aliskiren-containing products, Rasilez and Rasilez HCT, after … Continue reading

Posted in Pharmaceuticals, Tekturna |

Tekturna To Undergo Canadian Safety Review

High blood pressure drug, Tekturna, will undergo a Canadian Safety Review after a clinical study was halted by drug maker, Novartis, over unexpected adverse reactions. “Specifically, when used in combination with other blood pressure-lowering drugs known as angiotensin-converting enzyme (ACE) … Continue reading

Posted in Tekturna |

© 2005-2019 Parker Waichman LLP ®. All Rights Reserved.